Evidence-based summaries of current menopause research
Peer-reviewed data on menopause treatments, risks, and outcomes. Each summary distills the numbers behind the claims so you can make informed decisions.
Hot flashes last a median of 7.4 years, not the few years women are told. Hormone therapy cuts frequency by about 75 percent. Among nonhormonal choices, the newest receptor antagonist class (fezolinetant, then elinzanetant) matches hormones on frequency, while 79 percent of the reported benefit of the SSRI paroxetine was placebo response.
Aging, not menopause, drives most midlife weight gain. The transition adds a separate effect: fat redistributes to the abdomen, raising visceral adiposity independent of total weight. Exercise evidence is strong, from 101 RCTs and 5,697 postmenopausal women. Diet data targeting the transition specifically is thin.
Genitourinary syndrome of menopause affects roughly half or more of postmenopausal women yet is widely under-treated. The evidence on low-dose vaginal estrogen (the best-studied treatment, working within weeks), moisturizers and lubricants, vaginal DHEA, ospemifene, and the unproven durability of laser and radiofrequency devices.
Palpitations affect up to 42% of midlife women. The research on cardiovascular changes during menopause, when palpitations signal something serious, and what interventions reduce heart disease risk. SWAN Heart Study data, the AHA scientific statement, and new ambulatory ECG evidence from the Menopause Racing Heart Pilot Study.
Why friendships change during menopause. Over one-third of women report increased desire for solitude. Hormonal effects on social reward, vasomotor-driven social avoidance, and the midlife re-evaluation that reshapes your social circle. Three drivers, the data on what works, and the research on why some relationships don't survive this phase.
The real numbers on progression from osteopenia to osteoporosis. Annual conversion rates, fracture risk by T-score, and what actually changes your bone density trajectory. HRT reduces hip fracture risk by 34-39%, exercise preserves BMD, and most women with osteopenia never reach the osteoporosis threshold.
Aerobic for blood pressure, HIIT for inflammation, mind-body for sleep, heavy resistance for bones. The evidence on which exercise types work for which menopause symptoms and how much you need.
Testosterone therapy is the least prescribed but most requested menopause intervention. The evidence on libido, bone density, muscle mass, cognition, and cardiovascular safety in women.
The 2002 Women's Health Initiative trial triggered a decade of fear-driven avoidance of hormone therapy. The reanalysis tells a different story. For most symptomatic women under 60, HRT is safer than the conditions it treats.
Forty to sixty percent of women experience clinically significant sleep disruption during the menopause transition. The evidence on HRT, CBT-I, exercise, and melatonin. Vasomotor-driven sleep disruption and primary insomnia are not the same condition and do not respond to the same treatments.
The evidence on cognitive changes during menopause. What happens to memory, focus, and verbal fluency. Which interventions have data behind them and which do not.
Atypical femur fractures, rebound fractures after stopping denosumab, cardiovascular risk with romosozumab, osteonecrosis of the jaw, and network meta-analysis rankings. The actual numbers behind the scare stories.